Thinking differently about neurodevelopmental disorders and autism: Lumping vs. splitting

  • Autism Research
Speaker Evdokia Anagnostou, M.D.
Bloorview Research Institute
Date & Time


Location

Gerald D. Fischbach Auditorium
160 5th Avenue
New York, NY 10010 United States

Tea: 4:15 – 5:00pm
Lecture: 5:00 – 6:15pm

Autism Research

Autism Research lectures bring together scientists and scholars to discuss diverse and important topics related to autism. The lectures are open to the public and are held at the Gerald D. Fischbach Auditorium at the Simons Foundation headquarters in New York City. Tea is served prior to each lecture.

Video replay of this event will be available shortly. Please check back at a later date.

On September 26, 2018, Evdokia Anagnostou will discuss the challenge of rethinking classification systems and diagnostic labels for autism and related neurodevelopmental disorders in light of recent findings from research and clinical studies.

Her talk is part of the Simons Foundation Autism Research lecture series.

About the Lecture

There has been an explosion of discoveries furthering our understanding of the biology and the various presentations of autism spectrum disorder and other neurodevelopmental differences. The excitement from the new understandings is matched by the challenge to rethink our classification systems and diagnostic labels and translate that into meaningful treatments.

In this lecture, Evdokia Anagnostou will use evidence from genetics, brain imaging and behavior as well as treatment studies to illustrate this emerging rethinking of neurodevelopmental conditions.

About the Speaker

Evdokia Anagnostou is a child neurologist and senior clinician scientist at Holland Bloorview Kids Rehabilitation Hospital; associate professor in the Department of Pediatrics at the University of Toronto; assistant director of the Bloorview Research Institute and co-lead of the Autism Research Centre. She holds a Canada Research Chair in translational therapeutics in autism spectrum disorder and the Dr. Stuart D. Sims Chair in Autism at Holland Bloorview Kids Rehabilitation Hospital.

Anagnostou’s research focuses on translating genomic and systems biology findings into novel treatments for autism spectrum disorder.

Past Lectures

Thinking differently about neurodevelopmental disorders and autism: Lumping vs. splitting

Evdokia Anagnostou, M.D.Assistant Director, Bloorview Research Institute
Child Neurologist and Senior Clinician Scientist, Holland Bloorview Kids Rehabilitation Hospital
Associate Professor, Department of Pediatrics, University of Toronto

On September 26, 2018, Evdokia Anagnostou will discuss the challenge of rethinking classification systems and diagnostic labels for autism and related neurodevelopmental disorders in light of recent findings from research and clinical studies.

Autism genetics: Where have we been and where are we going?

Matthew State, M.D., Ph.D.Oberndorf Family Distinguished Professor and Chair, University of California, San Francisco

On April 10, 2018, Matthew State reviewed the progress that has been made in autism genetics over the past 10 years and the role that the Simons Simplex Collection (SSC) played in this (r)evolution. He also addressed the potential contribution of ongoing genomic studies including whole-genome sequencing as well as the challenges and opportunities of leveraging the genetic findings to identify pathophysiological mechanisms.

On the road to precision health: Brain-based biomarkers in autism spectrum disorder

Shafali Spurling Jeste, M.D.Associate Professor in Psychiatry, Neurology and Pediatrics, University of California, Los Angeles
Director, Developmental Neurophysiology Lab, Center for Autism Research and Treatment, University of California, Los Angeles

On 7 February 2018, Shafali Spurling Jeste provided a topical overview of the current state of research in autism biomarkers. She shared data from studies of autism biomarkers in three key areas: early risk prediction (studies of high-risk infants), heterogeneity within the autism spectrum and genetically defined subgroups within autism. Finally, she discussed the challenges around clinical trial design and development and considered how more objective measures of brain function can improve clinical trials.

Subscribe to our newsletter and receive SFARI funding announcements and news